Figure 4
Effects of SRTAW04 on neuronal loss in the optic nerve. Neurofilament stained optic nerves from a representative (a) control, (b) RSMHV2 infected, (c) RSA59 infected, (d) RSA59 infected, with SRTAW04 treatment and (e) RSA59 infected, with SRTAW04 + EX527 treatment demonstrate normal axonal staining (a,b,d) and areas of axonal loss (c,e). Scale bars 100 μm for a-e. (f) Neurofilament staining of the optic nerve 30 days postinoculation demonstrates significant loss (*p < 0.05) of axons in mice infected with RSA59 (n = 26) compared to normal axonal staining in control (n = 12) and RSMHV2-infected (n = 10) mice. SRTAW04 treatment (n = 16) shows a significant preservation (@@p < 0.01) of the axons compared to RSA59 infected mice. SRTAW04 treatment group with EX527 co-treatment (n = 22) shows significant reduction (*p < 0.05) in axonal staining compared to the RSA59 with SRTAW04 treatment group.